Cardiovascular safety of the dipetidyl peptidase‐4 inhibitor alogliptin in type 2 diabetes mellitus

ConclusionThese analyses have not shown a signal of increased CV risk with alogliptin in patients with type 2 diabetes. Future results from the adequately powered EXAMINE trial will definitively assess the CV safety profile of aloglipin in patients with type 2 diabetes mellitus.

Source: Diabetes, Obesity and Metabolism - April 4, 2013 Category: Endocrinology Authors: W. B. White, R. Pratley, P. Fleck, M. Munsaka, M. Hisada, C. Wilson, V. Menon Tags: ORIGINAL ARTICLE Source Type: research